{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:08:45Z","timestamp":1772118525249,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin City","doi-asserted-by":"publisher","award":["18JCZDJC45100"],"award-info":[{"award-number":["18JCZDJC45100"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin City","doi-asserted-by":"publisher","award":["19JCYBJC26500"],"award-info":[{"award-number":["19JCYBJC26500"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770213"],"award-info":[{"award-number":["81770213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study aimed to identify the prognostic factors in patients with Waldeyer's ring diffuse large B\u2010cell lymphoma (WR\u2010DLBCL), comparing the efficacy of radiotherapy (RT) for the WR\u2010DLBCL patients in the pre\u2010rituximab and rituximab eras. We conducted a retrospective analysis of 134 patients diagnosed with WR\u2010DLBCL. Univariate and multivariate analyses were performed to identify the prognostic factors for WR\u2010DLBCL. Then, we divided these patients into the rituximab plus chemotherapy group (R\u2010chemotherapy) (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a088) and chemotherapy group (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a046), and the Kaplan\u2013Meier and Cox regression model analyses were applied to investigate the treatment value of RT in both the groups. Multivariate analysis revealed international prognostic index (IPI)\u00a0\u2265\u00a03 and chemotherapy without rituximab as significant risk factors for the progression\u2010free survival (PFS, IPI\u00a0\u2265\u00a03:\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.001; chemotherapy without rituximab:\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.002) and overall survival (OS, IPI\u00a0\u2265\u00a03,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u00a00.001; chemotherapy without rituximab,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.024). Rituximab combined with chemotherapy significantly improved PFS (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.002) and OS (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.006) in these patients. RT did not significantly contribute to the survival in the overall cohort analysis, whereas in the subgroup analysis, RT significantly improved the PFS (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.025) and OS (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.029) for the patients in the chemotherapy group, but not in the R\u2010chemotherapy group. In conclusion, the WR\u2010DLBCL patients could benefit from RT in the pre\u2010rituximab era, whereas the addition of rituximab to chemotherapy significantly improved the survival of WR\u2010DLBCL patients, and the clinical benefit of RT was reduced.\n                  <\/jats:p>","DOI":"10.1002\/hon.2869","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T02:27:41Z","timestamp":1619576861000},"page":"490-497","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Reduced radiotherapy clinical benefit for primary Waldeyer's ring diffuse large B\u2010cell lymphoma in the rituximab era"],"prefix":"10.1002","volume":"39","author":[{"given":"Qingpei","family":"Guan","sequence":"first","affiliation":[{"name":"Departments of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin's Clinical Research Center for Cancer the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuheng","family":"Hong","sequence":"additional","affiliation":[{"name":"Departments of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin's Clinical Research Center for Cancer the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Hu","sequence":"additional","affiliation":[{"name":"Departments of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin's Clinical Research Center for Cancer the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiqi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Departments of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin's Clinical Research Center for Cancer the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanfang","family":"Li","sequence":"additional","affiliation":[{"name":"Departments of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin's Clinical Research Center for Cancer the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengzi","family":"Qian","sequence":"additional","affiliation":[{"name":"Departments of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin's Clinical Research Center for Cancer the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Departments of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin's Clinical Research Center for Cancer the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiubao","family":"Ren","sequence":"additional","affiliation":[{"name":"Departments of Immunology\/Biotherapy Tianjin Medical University Cancer Institute and Hospital  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Qiu","sequence":"additional","affiliation":[{"name":"Departments of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin's Clinical Research Center for Cancer the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7663-2923","authenticated-orcid":false,"given":"Xianhuo","family":"Wang","sequence":"additional","affiliation":[{"name":"Departments of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin's Clinical Research Center for Cancer the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Departments of Lymphoma Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin's Clinical Research Center for Cancer the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,4,27]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197809)42:3<1096::AID-CNCR2820420310>3.0.CO;2-Z"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1052-5149(03)00039-X"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e318261084b"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-6-77"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109097720"},{"issue":"2","key":"e_1_2_10_7_1","first-page":"1543","article-title":"Prognosis and treatment strategies of primary B\u2010cell and NK\/T\u2010cell nasopharyngeal non\u2010Hodgkin\u2019s lymphoma at early stage","volume":"25","author":"Zou GR","year":"2006","journal-title":"Chin J Canc"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.155"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.1077"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1856-4"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008313229892"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds150"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.3441"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2478\/raon-2019-0045"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0964-1955(95)00058-5"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e318187ddbb"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.710907"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_10_20_1","volume-title":"A language and environment for statistical computing","author":"R Core Team. R","year":"2020"},{"key":"e_1_2_10_21_1","first-page":"2","volume-title":"A Package for Survival Analysis in R","author":"Therneau TM","year":"2020"},{"key":"e_1_2_10_22_1","volume-title":"Survminer: Drawing Survival Curves Using \u2018ggplot2\u2019","author":"Kassambara A","year":"2020"},{"key":"e_1_2_10_23_1","volume-title":"Forestplot: Advanced Forest Plot Using \u2018grid\u2019 Graphics","author":"Gordon M","year":"2020"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.07.006"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000375"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2869","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2869","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T15:05:41Z","timestamp":1692975941000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,27]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1002\/hon.2869"],"URL":"https:\/\/doi.org\/10.1002\/hon.2869","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.2869\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2869\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2869\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2869\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2869\/v2\/decision1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,27]]},"assertion":[{"value":"2021-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}